{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+per+week", "query": { "intervention": "Placebo once per week" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 604, "total_pages": 61, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+per+week&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-19T00:43:04.808Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00712673", "title": "GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2008-06", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00712673" }, { "nct_id": "NCT02858453", "title": "Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Interstitial Cystitis", "Bladder Pain Syndrome", "Painful Bladder Syndrome", "Chronic Interstitial Cystitis" ], "interventions": [ { "name": "AQX-1125 100 mg", "type": "DRUG" }, { "name": "AQX-1125 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aquinox Pharmaceuticals (Canada) Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 433, "start_date": "2016-07", "completion_date": "2020-02", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 56, "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858453" }, { "nct_id": "NCT02483975", "title": "Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Albuterol/Salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 111, "start_date": "2015-10-09", "completion_date": "2016-06-21", "has_results": true, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02483975" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT03653026", "title": "A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 522, "start_date": "2018-12-06", "completion_date": "2021-01-14", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 114, "location_summary": "Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03653026" }, { "nct_id": "NCT06173778", "title": "Semaglutide for Post-Smoking Cessation Weight Management", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight", "Cigarette Smoking" ], "interventions": [ { "name": "semaglutide 2.4mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nicotine Replacement Therapy (NRT, nicotine patch)", "type": "DRUG" }, { "name": "Brief Smoking Cessation Counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 197, "start_date": "2024-04-23", "completion_date": "2026-08-01", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 2, "location_summary": "Austin, Texas • Houston, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06173778" }, { "nct_id": "NCT00073333", "title": "Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Social Phobia" ], "interventions": [ { "name": "Social Skills Training", "type": "BEHAVIORAL" }, { "name": "Exposure Treatment", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2002-12", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073333" }, { "nct_id": "NCT02500147", "title": "Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Polycystic Ovary Syndrome", "Non-Alcoholic Fatty Liver Disease", "Metabolic Syndrome" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "25 Years", "sex": "FEMALE", "summary": "13 Years to 25 Years · Female only" }, "enrollment_count": 3, "start_date": "2011-09-08", "completion_date": "2021-03-03", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500147" }, { "nct_id": "NCT01751984", "title": "A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "ETC-1002", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 56, "start_date": "2012-10-04", "completion_date": "2013-05-01", "has_results": true, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 5, "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Raleigh, North Carolina + 2 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01751984" }, { "nct_id": "NCT01058096", "title": "Safety and Efficacy of Cariprazine for Mania", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder", "Mania" ], "interventions": [ { "name": "Cariprazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 323, "start_date": "2010-02", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-09-19T00:43:04.808Z", "location_count": 10, "location_summary": "Long Beach, California • Riverside, California • San Diego, California + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Charles", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058096" } ] }